Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
McKinsey
AstraZeneca
Merck
Dow

Last Updated: September 26, 2022

Details for Patent: 6,858,584


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 6,858,584 protect, and when does it expire?

Patent 6,858,584 protects VIBATIV and is included in one NDA.

This patent has ninety-three patent family members in thirty-four countries.

Summary for Patent: 6,858,584
Title: Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Abstract:Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
Inventor(s): Judice; J. Kevin (El Granada, CA), Shaw; Jeng-Pyng (Saratoga, CA), Mu; YongQi (Los Altos, CA), Conner; Michael W. (Half Moon Bay, CA), Pace; John L. (San Anselma, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:09/846,893
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 6,858,584

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-001 Sep 11, 2009 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,858,584

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 035333 See Plans and Pricing
Austria 337334 See Plans and Pricing
Austria 388960 See Plans and Pricing
Austria 402951 See Plans and Pricing
Austria 416791 See Plans and Pricing
Australia 2001261107 See Plans and Pricing
Australia 5746401 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKesson
Boehringer Ingelheim
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.